Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.
Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105.
Chiesi Farmaceutici SpA has prepared azetidine derivatives acting as cathepsin C (dipeptidyl peptidase 1, DPP-1) inhibitors and reported to be useful for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), among others.
Burn injuries, including those induced by chemicals, may have systemic effects, and can lead to acute lung injury (ALI). Chemical burn injuries account for about 2% to 5% of total skin burn injuries. Among the chemicals, vesicating agents like Lewisite are particularly relevant due to the lack of antidotes.
A common molecular pathway associated with lung fibrosis may also hold the key to pulmonary vascular repair. A group of scientists at the University of Pennsylvania (Penn) found that when a viral infection damaged these vessels, the injury could be restored by activating the transforming growth factor-β receptor 2 (TGF-βR2) in endothelial cells, which led to cell proliferation.
RSS
